财务表现 - Elevance Health (ELV)在2023年12月的季度报告中，每股收益为5.62美元，超过了Zacks Consensus Estimate的5.55美元，同比去年的5.23美元有所增长[1] - 公司在过去四个季度中，四次超过了市场预期的每股收益[3] - Elevance Health的营收为424.5亿美元，超过了Zacks Consensus Estimate的1.51%，过去四个季度中有三次超过市场预期的营收[4] 股价表现 - 公司股价在年初以来仅增长了0.1%，表现不如标普500指数的2%[6] 盈利前景 - 公司的盈利前景对股价走势有重要影响，当前的盈利预期为每股10.41美元，营收429.1亿美元，预计股价将会表现优于市场[9] 行业排名 - 医疗服务行业的前景对公司股价表现也有重要影响，目前医疗服务行业在250多个Zacks行业中排名倒数34%，研究显示排名前50%的行业表现要比排名后50%的行业好两倍以上[10]

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2023 results. “We are pleased to have delivered another year of strong performance in 2023, enabled by our relentless focus on customer experience and affordability, and continued investments in growth and innovation. The balance and resilience of our business coupled with the focused execution of our enterprise strategy supports our confidence in our outlook for 2024, as we continue to optimize the found ...

Wall Street analysts forecast that Elevance Health (ELV) will report quarterly earnings of $5.55 per share in its upcoming release, pointing to a year-over-year increase of 6.1%. It is anticipated that revenues will amount to $41.82 billion, exhibiting an increase of 5.4% compared to the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course o ...

Elevance Health, Inc. (ELV) is set to report its fourth-quarter 2023 results on Jan 24, before the opening bell. This time around, the company’s overall earnings performance is likely to have received a boost from higher segmental profits, only to be undone by reduced total medical memberships and higher costs.What Do the Estimates Say?The Zacks Consensus Estimate for fourth-quarter earnings per share of $5.55 suggests a 6.1% increase from the prior-year figure of $5.23. The consensus mark remained stable o ...

Investors with an interest in Medical Services stocks have likely encountered both Elevance Health (ELV) and HealthEquity (HQY) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate re ...

Elevance Health - Elevance Health是医疗行业的一员，拥有Zacks Sector Rank排名第5[2] - Elevance Health目前的Zacks Rank为2（买入），显示其盈利前景较为乐观[3] - Elevance Health今年以来的回报率为0.4%，表现优于医疗行业平均回报率-0.7%[5] - Elevance Health属于医疗服务行业，今年以来的回报率优于该行业平均回报率-6.3%[8] Axonics Modulation Technologies - Axonics Modulation Technologies是另一家医疗股票，今年以来表现优于行业，回报率为9.8%[6] - Axonics Modulation Technologies当前的Zacks Rank为1（强烈买入），盈利预期增长186.5%[7] - Axonics Modulation Technologies属于医疗信息系统行业，该行业今年以来回报率增长18.2%[9] - 投资者应继续关注Elevance Health和Axonics Modulation Technologies，因为它们可能会保持良好的表现[10]

Elevance Health, Inc. (ELV) is positioned for growth with premium rate adjustments in the Health Benefits business, an expanding external pharmacy membership base and overall strength in the Carelon business. The BioPlus acquisition is expected to continue supporting the Carelon unit’s performance.Elevance — with a market cap of $111.6 billion — is one of the largest publicly traded health benefits companies in the United States. Courtesy of solid prospects, this currently Zacks Rank #3 (Hold) stock is wort ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?T ...

The most recent trading session ended with Elevance Health (ELV) standing at $475.12, reflecting a -1.49% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.08%. Elsewhere, the Dow saw a downswing of 0.31%, while the tech-heavy Nasdaq appreciated by 0.02%.The the stock of health insurer has risen by 0.51% in the past month, lagging the Medical sector's gain of 6.57% and the S&P 500's gain of 3.52%.Analysts and investors alike will be keeping a close eye on the per ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...